HomeCompareNOXOF vs PM

NOXOF vs PM: Dividend Comparison 2026

NOXOF yields 4444.44% · PM yields 3.48%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NOXOF wins by $19857738408180.43M in total portfolio value
10 years
NOXOF
NOXOF
● Live price
4444.44%
Share price
$0.05
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$19857738408180.48M
Annual income
$19,016,069,933,146,186,000.00
Full NOXOF calculator →
PM
Philip Morris International
● Live price
3.48%
Share price
$165.34
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,492.02
Full PM calculator →

Portfolio growth — NOXOF vs PM

📍 NOXOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNOXOFPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NOXOF + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NOXOF pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NOXOF
Annual income on $10K today (after 15% tax)
$377,777.78/yr
After 10yr DRIP, annual income (after tax)
$16,163,659,443,174,257,000.00/yr
PM
Annual income on $10K today (after 15% tax)
$296.12/yr
After 10yr DRIP, annual income (after tax)
$2,118.22/yr
At 15% tax rate, NOXOF beats the other by $16,163,659,443,174,255,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NOXOF + PM for your $10,000?

NOXOF: 50%PM: 50%
100% PM50/50100% NOXOF
Portfolio after 10yr
$9928869204090.26M
Annual income
$9,508,034,966,573,095,000.00/yr
Blended yield
95.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

NOXOF
No analyst data
Altman Z
-7.9
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.5% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NOXOF buys
0
PM buys
0
No recent congressional trades found for NOXOF or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNOXOFPM
Forward yield4444.44%3.48%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$19857738408180.48M$49.6K
Annual income after 10y$19,016,069,933,146,186,000.00$2,492.02
Total dividends collected$19800558376185.16M$11.7K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: NOXOF vs PM ($10,000, DRIP)

YearNOXOF PortfolioNOXOF Income/yrPM PortfolioPM Income/yrGap
1← crossover$455,144$444,444.44$11,648$408.29+$443.5KNOXOF
2$19,392,277$18,905,272.87$13,589$495.90+$19.38MNOXOF
3$773,548,232$752,798,494.96$15,877$603.21+$773.53MNOXOF
4$28,891,953,466$28,064,256,857.57$18,580$734.88+$28891.93MNOXOF
5$1,010,538,077,568$979,623,687,360.21$21,781$896.75+$1010538.06MNOXOF
6$33,103,483,882,921$32,022,208,139,922.89$25,578$1,096.12+$33103483.86MNOXOF
7$1,015,787,352,937,823$980,366,625,183,097.90$30,092$1,342.17+$1015787352.91MNOXOF
8$29,201,617,438,828,424$28,114,724,971,184,950.00$35,470$1,646.46+$29201617438.79MNOXOF
9$786,606,051,433,916,900$755,360,320,774,370,600.00$41,892$2,023.58+$786606051433.88MNOXOF
10$19,857,738,408,180,478,000$19,016,069,933,146,186,000.00$49,578$2,492.02+$19857738408180.43MNOXOF

NOXOF vs PM: Complete Analysis 2026

NOXOFStock

Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.

Full NOXOF Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this NOXOF vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NOXOF vs SCHDNOXOF vs JEPINOXOF vs ONOXOF vs KONOXOF vs MAINNOXOF vs MONOXOF vs BTINOXOF vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.